🔍 See what insiders are buying — free 7-day trial, no credit card required.
Get started →
BIIB
NASDAQ
🇺🇸 US
Biogen Inc.
Pharmaceuticals
26Score
DipBuster Score™
$208.45
+$6.63 (+3.29%)
Live price · Source: Yahoo
52-Week Position
$127.00
88% of range
$219.72
Beta
0.158
Low vol
Dividend
—
no income
Mkt Cap
N/A
total value
Mkt CapN/A
P/EN/A
DividendNone
Beta0.158
52W High$219.72
52W Low$127.00
DipBuster Brief
Key signals at a glance
Zone: Consider Trimming
Bearish
Near 52-Week High — Asymmetric Risk
At 88% of its annual range the stock is close to its peak. New buyers face limited upside and meaningful downside if sentiment shifts.
Neutral
Earnings Data Unavailable
P/E ratio could not be determined — this is common for early-stage, loss-making, or recently-listed companies.
Valuation
P/E Ratio—
Mkt CapN/A
52W Position88% of range
EV/EBITDA—
Cash Flow
FCF Yield—
FCF / Share
Op. Cash Flow—
Margins
Gross Margin—
Op. Margin—
Net Margin—
Balance Sheet
Cash—
Total Debt—
Net Cash—
Dividend
Yield—
Annual / shNone
Beta0.158
🔒
FCF, margins & balance sheet data are hidden — create a free account to see them.
🕵️ Insiders
📊 Valuation
💰 Dividends
📰 News
🤖 AI Analysis
Recent director dealings and insider transactions at Biogen Inc. (BIIB), from SEC Form 4 filings. Open-market buys by directors spending their own money are one of the strongest signals in investing.
| Date | Insider | Type | Shares |
|---|---|---|---|
| 2026-06-09 | Minor Lloyd | BUY | 1,505 |
| 2026-06-09 | Pangalos Menelas N | SELL | 2,370 |
| 2026-06-09 | Pangalos Menelas N | BUY | 1,505 |
| 2026-06-09 | Pangalos Menelas N | BUY | 2,370 |
| 2026-06-09 | Langer Susan | BUY | 1,505 |
| 2026-06-09 | Patolawala Monish D | BUY | 1,505 |
| 2026-06-09 | Mantas Jesus B | BUY | 1,505 |
| 2026-06-09 | Freire Maria C | BUY | 2,005 |
| 2026-06-09 | Rowinsky Eric K | BUY | 1,505 |
| 2026-06-09 | Hawkins William A | BUY | 1,505 |
Valuation
P/E RatioN/A
Market CapN/A
Beta0.158
Dividend/yrNone
52W High$219.72
52W Low$127.00
52-Week Range
$127.00Now$219.72
88% through annual range
From 52W High−5.1%
From 52W Low+64.1%
📖 Plain English Summary
Biogen Inc. is at 88% of its 52-week range. Beta 0.158 — tends to move less than the market.
🏦 Analyst Price Target
Loading…
🎯 Analyst Revenue & EPS Estimates
Loading estimates…
🔄 Peer Comparison
Loading peers…
Loading dividend data…
Latest news for BIIB
🟢 Bullish
⬜ Neutral
🔴 Bearish
🤖
DipBuster AI Analysis — BIIB
Heuristic · balance sheet, insider filings, price data, academic research
Biogen Inc. — DipBuster Score 26/100
Graham value assessment, NCAV analysis, price zones...
Insider signals, cluster detection, risk factors...
Track Biogen Inc. free
Add BIIB to a watchlist, set insider-buy and price alerts, and get the full financial picture — free account, no card.
Sponsored · FCA Regulated Broker
Trading 212
Commission-free investing. ISA and GIA available. FCA regulated.
Free share worth up to £100 when you sign up
Capital at risk. Your investments can go down as well as up. Disclaimer
DipBuster Score™ Breakdown
Value & P/E
0/30
Dip Position
5/25
Momentum & Volume
16/25
Quality & Size
5/10
Insider Activity
0/10
🎯 Dip Buyer Signal
9
/100 · NEUTRAL
dip depth
0/25
oversold rsi
0/25
mean reversion
0/15
insider zone
8/25
capitulation
0/10
Insiders' avg buy price: $195.04 — marked 🟡 on the chart above.
Technical signal only. Not financial advice.
Quick Take
⚪
Not a Dip
DipBuster Score: 26/100
📈
Strong recent momentum — price and volume trending in the right direction.
Company Profile
Biogen Inc. is a leading biotechnology firm dedicated to the discovery, development, production, and distribution of treatments for complex neurological and neurodegenerative conditions. Its established portfolio include…
Sector
Pharmaceuticals
Market
🇺🇸 US
CEO
Christopher A. Viehbacher
Staff
7,500 employees
Website